- Frazier Healthcare Partners today announced the closure of a $617 million fund, also known as Frazier Life Sciences X. The fresh cash will be used to invest in therapeutics-focused companies developing and commercializing biopharmaceuticals.
- The fund will invest across all company stages, with two-thirds of investments going toward seed and series A rounds.
- Founded in 1991, Frazier has offices in Seattle and Silicon Valley. It has raised $4.8 billion over its lifetime and has invested in more than 200 companies to date.
- Frazier also has a Healthcare Growth Buyout Fund, which raised $780 million in April 2018.
- The firm announced new promotions on its Life Sciences team. Dan Estes, Ph.D., to General Partner; Jamie Brush, M.D., to Partner; Gordon Empey, J.D., to Partner and General Counsel; Aditya Kohli, Ph.D., to Principal (Operating Professional); and Liz Park to Vice President of Investor Relations.
- U.S. venture capital deal activity in life sciences reached $22.2 billion across 1,547 deals in 2019, according to PitchBook. slightly down from $24.6 billion in 2018.
Like what you're reading? Subscribe to GeekWire's free newsletters to catch every headline